Featured Research

from universities, journals, and other organizations

New approach to chronic lymphocytic leukemia treatment

Date:
March 14, 2014
Source:
Norris Cotton Cancer Center/Dartmouth-Hitchcock Medical Center
Summary:
A novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant, as been developed by scientists. Unlike other novel therapies that have shown promise in the treatment of CLL, this approach is unique because it does not directly target proteins within the B-cell receptor pathway, but instead uses novel model systems that reverse the pro-survival effects of the microenvironment.

Dartmouth researchers have developed a novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant. The researchers, led by Alexey V. Danilov, MD, PhD, assistant professor at the Geisel School of Medicine at Dartmouth and Hematologist-Oncologist at the Norris Cotton Cancer Center, modeled the lymph node microenvironment where CLL cells are found in the laboratory. They were able to disrupt the activity of a pathway (NF-kappaB) that ensures the survival and resistance of the CLL cells in such microenvironments.

Related Articles


The study findings were published in the March 15, 2014 issue of Clinical Cancer Research.

“In this in vitro microenvironment, we used MLN4924 to disrupt the activity of the NF-kappaB pathway by targeting Nedd8, which controls activation of NF-kappaB,” said Danilov. “This decreased the survival of CLL cells and re-sensitized them to conventional chemotherapy as well as novel agents. Because the CLL cells used were obtained from patients with this disorder, these findings are immediately relevant to the clinic.”

Danilov says that unlike other novel therapies that have shown promise in the treatment of CLL, this approach is unique because it does not directly target proteins within the B-cell receptor pathway. He also notes that other research models that mimic the natural lymph node microenvironment have typically induced prolonged survival of CLL cells and made them resistant to in vitro chemotherapy. This research used novel model systems which reversed the pro-survival effects of the microenvironment.

The researchers are now working to understand the intricate mechanisms of how MLN4924 decreased the survival of CLL cells. Once they understand the mechanisms involved, new therapeutic approaches and drug combinations can be developed for use in animal studies of CLL, and may ultimately lead to a clinical trial with human patients.


Story Source:

The above story is based on materials provided by Norris Cotton Cancer Center/Dartmouth-Hitchcock Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. C. Godbersen, L. A. Humphries, O. V. Danilova, P. E. Kebbekus, J. R. Brown, A. Eastman, A. V. Danilov. The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells. Clinical Cancer Research, 2014; 20 (6): 1576 DOI: 10.1158/1078-0432.CCR-13-0987

Cite This Page:

Norris Cotton Cancer Center/Dartmouth-Hitchcock Medical Center. "New approach to chronic lymphocytic leukemia treatment." ScienceDaily. ScienceDaily, 14 March 2014. <www.sciencedaily.com/releases/2014/03/140314111344.htm>.
Norris Cotton Cancer Center/Dartmouth-Hitchcock Medical Center. (2014, March 14). New approach to chronic lymphocytic leukemia treatment. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2014/03/140314111344.htm
Norris Cotton Cancer Center/Dartmouth-Hitchcock Medical Center. "New approach to chronic lymphocytic leukemia treatment." ScienceDaily. www.sciencedaily.com/releases/2014/03/140314111344.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins